Regenxbio
RGNX
172 hedge funds and large institutions have $1.16B invested in Regenxbio in 2021 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 69 increasing their positions, 47 reducing their positions, and 30 closing their positions.
60% more call options, than puts
Call options by funds: $4.83M | Put options by funds: $3.02M
47% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 47
4.69% more ownership
Funds ownership: 78.4% → 83.09% (+4.7%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
5% less funds holding
Funds holding: 182 → 172 (-10)
17% less capital invested
Capital invested by funds: $1.4B → $1.16B (-$239M)
27% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$30M |
| 2 |
JP Morgan Chase
New York
|
+$29.4M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$13.3M |
| 4 |
BlackRock
New York
|
+$7.14M |
| 5 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$5.94M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Korea Investment Corp
Seoul,
South Korea
|
-$16.5M |
| 2 |
Two Sigma Investments
New York
|
-$6.33M |
| 3 |
CG
Carmignac Gestion
Paris,
France
|
-$4.34M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$3.77M |
| 5 |
PA
Perceptive Advisors
New York
|
-$3.74M |
RGNX Hedge Fund Activity: Q4 2021 in Review
172 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Regenxbio (RGNX) for Q4 2021, worth a combined $1.16B — down 17% from $1.4B a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of RGNX and 22 opened new positions — a net loss of 8 holders — while 47 trimmed existing stakes and 69 added.
The largest buyer was Sofinnova Investments, adding an estimated $30M. The largest seller was Korea Investment Corp, exiting entirely with an estimated $16.5M sold.
- 172 institutional investors held Regenxbio (RGNX) as of Q4 2021, down from 182 in Q3 2021.
- Funds reported $1.16B of Regenxbio stock for Q4 2021, down 17% quarter-over-quarter.
- 22 funds opened new Regenxbio positions in Q4 2021 and 30 closed out, a net change of -8 holders.
- The largest Regenxbio buyer in Q4 2021 was Sofinnova Investments, an estimated $30M added.
- The largest Regenxbio seller in Q4 2021 was Korea Investment Corp, an estimated $16.5M sold.
Based on aggregated 13F filings for Q4 2021.